Yes, many people take Empliciti (elotuzumab) for multiple myeloma. Here are some key points about the medication:

- Combination Therapy: Empliciti is often combined with Pomalyst or Revlimid and a corticosteroid
- Mechanism: It is a monoclonal antibody that helps the immune system recognize and attack myeloma cells.
- Show Full Answer

Yes, many people take Empliciti (elotuzumab) for multiple myeloma. Here are some key points about the medication:

- Combination Therapy: Empliciti is often combined with Pomalyst or Revlimid and a corticosteroid.
- Mechanism: It is a monoclonal antibody that helps the immune system recognize and attack myeloma cells.
- Administration: Empliciti is administered as an intravenous infusion.
- Common Side Effects: Fatigue, diarrhea, fever, constipation, cough, cold or flu symptoms, nausea, loss of appetite, peripheral neuropathy, and pneumonia.
- Serious Side Effects: Infusion reactions, increased risk of infection, increased risk of developing other cancers, and liver damage.

For more details, you can visit the Empliciti page on MyMyelomaTeam.

 This AI-generated response comes from MyMyelomaTeam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

Empliciti (Elotuzumab) for Myeloma | MyMyelomaTeam

Medications for Multiple Myeloma: Your Guide | MyMyelomaTeam